Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE(®), Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). The Liverpool R...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoecon Open
Main Authors: Fleeman, Nigel, Mahon, James, Nevitt, Sarah, Duarte, Rui, Boland, Angela, Kotas, Eleanor, Dundar, Yenal, McEntee, Joanne, Ahmad, Sajjad
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861391/
https://ncbi.nlm.nih.gov/pubmed/31240690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-0138-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados